Loading organizations...
§ Venture Capital · Cambridge, Massachusetts, United States, Northern America, North America
Strategic corporate venture capital fund backed by GSK, investing in early-stage bioelectronic medicine and neuromodulation.
Action Potential Venture Capital is a corporate venture capital fund based in Cambridge, Massachusetts, and Palo Alto, California, that invests globally in early-stage companies developing bioelectronic medicines and related enabling technologies. Backed by its corporate parent company GlaxoSmithKline with an initial $50 million fund commitment, the firm targets early-stage medical technology startups utilizing electrical signals to treat chronic diseases. The firm's active portfolio includes notable neuromodulation and medical device developers such as Cala Health, which secured a $77 million Series D funding round in November 2021. Action Potential Venture Capital also participated in a $150 million equity financing round for Saluda Medical in April 2023 and a $52 million Series B round for Alpheus Medical in May 2025. The strategic investment vehicle was officially founded in 2013 by Jens W. Eckstein and GlaxoSmithKline.
Key people at Action Potential Venture Capital.
Key people at Action Potential Venture Capital.
Action Potential Venture Capital (APVC) is a specialized medical technology venture capital firm founded in 2013 by GlaxoSmithKline (GSK). Its mission centers on advancing bioelectronic medicines and enabling technologies that regulate neural or cellular activity to treat chronic diseases. APVC invests primarily in companies leveraging hardware, computing, and material science innovations to develop neuromodulation and bioelectronic therapies. The firm plays a hands-on role in its portfolio companies, providing strategic guidance and board-level support. Key sectors include healthtech, biotech, hardware, robotics, and IoT, with notable portfolio companies such as Cala Health, CVRx, and Neuspera Medical. APVC's impact on the startup ecosystem is significant in fostering innovation in bioelectronic medicine, supporting diverse and inclusive healthcare entrepreneurship[1][2].
APVC was established in 2013 as the corporate venture capital arm of GSK, headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. The founding was driven by GSK’s strategic interest in bioelectronic medicine, a field combining biology and electronics to develop novel therapies. Key partners include Juan-Pablo Mas and Imran Eba, who bring deep expertise in venture capital, biotechnology, and medical device innovation. Juan-Pablo Mas, for example, has a background in electrical engineering and extensive experience in medical device R&D and strategy at Medtronic and Eli Lilly. The firm has evolved to focus on investments that integrate advances in hardware and computing with therapeutic applications, reflecting the growing importance of bioelectronic medicine[1][3].
APVC is riding the rising trend of bioelectronic medicine, an emerging field that merges electronics with biology to create therapies for chronic diseases that are often difficult to treat with traditional pharmaceuticals. The timing is critical as advances in hardware miniaturization, AI, and material science enable new therapeutic modalities. Market forces such as increasing chronic disease prevalence, demand for non-pharmaceutical treatment options, and regulatory acceptance of neuromodulation devices favor APVC’s investment thesis. By supporting startups that innovate at the intersection of hardware, software, and biology, APVC influences the broader ecosystem by accelerating the development and adoption of bioelectronic therapies, thereby shaping the future of medical treatment[1][4].
Looking ahead, APVC is well-positioned to capitalize on continued technological advances in AI, wearable devices, and minimally invasive therapies. The firm’s focus on bioelectronic medicine aligns with growing healthcare trends emphasizing personalized, device-based treatments. Future growth will likely involve expanding investments in AI-enabled diagnostics and therapeutics, as seen with recent investments like Exo Imaging. APVC’s influence may deepen as it helps bridge the gap between early-stage innovation and clinical adoption, potentially driving broader acceptance of bioelectronic therapies in mainstream medicine. This trajectory underscores APVC’s role as a key catalyst in transforming how chronic diseases are managed through technology[1][3][4].
Action Potential Venture Capital has more than 26 tracked investments across 18 companies. The latest tracked deal is $120.0M Series D in SetPoint Medical in August 2025.
